Jantar GmbH is a small pharmaceutical R&D company in the field of chronic rhinosinusitis. It developed a nasal spray and provided clinical proof that it alleviates all symptoms of the disease. A PCT patent has been filed. The identity of the active ingredient will be disclosed shortly.
Cooperation possibilities
Jantar is seeking an international partner for the conduct of a Phase III study as basis for market approval under a comprehensive collaboration and licensing agreement.
- https://www.jantar.ch
- +41 79 2549286
- Send an email
- Peter Schoch
Some insights
Chronic rhinosinusitis is the second most prevalent chronic inflammatory disease, with still unsatisfactory treatment options. JT-1 has the potential for a major therapeutic advance. It is based on a novel mechanism free of adverse effects and might provide relief to millions of patients.
Jantar is a one-man company. The entire preclinical and clinical development of the JT-1 nasal spray up to proving its clinical efficacy and patenting, was carried out single-handedly.
Most impressive are companies which build a bridge from the lab to the clinic based on cutting-edge science, imagination and persistence. Examples are Genentech (antibodies), BioNTech (immunotherapies based on mRNA) as well as Actelion and Indorsia (small molecules with novel mechanisms).
By providing a platform to introduce Jantar GmbH to potential investors/partners.
Jantar is seeking a collaboration with an international licensee to complete the development of the JT-1 nasal spray with a Phase III study as basis for market approval. Such a partner must therefore be active in the ORL indication field (chronic rhinosinusitis) and be interested in an OTC product.